Drug Discovery

A topic in the Science corpus, drawn from 16 papers.

Most-cited papers in Drug Discovery

Ordered by the recorded citation count from the source corpus; a citation is not an endorsement.

  1. Worldwide burden of cervical cancer in 2008. (2011, Annals of Oncology) — 1,104 citations
  2. Antioxidant activity, total phenolic and total flavonoid contents of whole plant extracts Torilis leptophylla L (2012, BMC Complementary and Alternative Medicine) — 1,096 citations
  3. Targeted Therapy in Salivary Gland Cancer: Prevalence of a Selected Panel of Actionable Molecular Alterations in a German Tertiary Referral Center Patient Cohort (2024, Molecular Diagnosis & Therapy) — 5 citations
  4. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours (2016)
  5. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions (2024)
  6. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). (2023)
  7. Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting (2024)
  8. DrugRepoChatter: A Drug Repurposing Expert Chatbot Curated by the REPO4EU Consortium (2024)
  9. A Phase II study of SHR-A1921, a TROP2-targeted antibody–drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma (2026)
  10. Trop2-targeted therapy in breast cancer (2024)
  11. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial (2023)
  12. Phase 2 trial of regorafenib in recurrent or metastatic adenoid cystic carcinoma (2024)
  13. Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies (2025)
  14. Nanomedicine-Driven Modulation of the Gut–Brain Axis: Innovative Approaches to Managing Chronic Inflammation in Alzheimer’s and Parkinson’s Disease (2025)
  15. Recent advances of antibody drug conjugates for clinical applications (2020)
  16. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics (2023)

Most active researchers

By papers in this topic: a volume measure, not trust.